Recursion’s August business update highlighted that Genentech opted its first neuroscience target into an early discovery ...
Tempus AI Inc. stocks have been trading up by 6.55 percent after bullish coverage on its AI-driven healthcare data platform.
When I set the dial by my ear to '1', I heard the sound of small gears meshing inside the helmet. The green circuit board visible through the small window flickered with a short electronic beep.
I am an advocate for AI and the vast possibilities for advancement it can bring across the world. Yet, these advancements ...
Introduction: Where is the speed of AI evolution heading?Hello everyone! This is MASATAN.We are now in the latter half of September 2026, and the movements in the AI industry are becoming even more ...
AI CTO and systems builder. CTO of Archdesk; founder of Lextron.ai, Inclify and Rejsomat. I write on enterprise AI, agents and Joule Wars. RSI AI refers to artificial intelligence capable of recursive ...
Recursion’s Genentech Collaboration Update Roche’s Genentech exercised the first Validated Target Option under its neuroscience collaboration with Recursion. The decision advanced a previously ...
Recursion Pharmaceuticals RXRX reported a loss of 25 cents per share in the second quarter of 2026, wider than the Zacks Consensus Estimate of a loss of 23 cents. The company had incurred a loss of 41 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results